ObjectiveaaPatients diagnosed with schizophrenia have reduced fecundity and premature mortality (both accidental and violent) with no obvious compensatory advantages among kin. The prevalence of the disorder is around 0.7/1%, higher than the expected prevalence of spontaneous mutations. Genes favoring schizophrenia may have been positively selected in the environment of evolutionary adaptation. Literature on potential adaptive genes is reviewed within an evolutionary framework.
INTRODUCTION
Recently Joo and co-workers 1 reported an association between single nucleotide polymorphisms in the V-akt murine thymoma viral oncogene homolog 1 (AKT1) gene and risk of obstetric complications in a large sample (n=180) of patients diagnosed with schizophrenia. The findings were open to interpretation, since they were statistically significant in female patients only and did not survive a correction for multiple testing. However, they add to a growing literature showing links between genes, schizophrenia and risk for somatic illness are more complicated than currently thought. 2, 3 The role of obstetric complications in schizophrenia is still debated. 4 Metaanalyses generally establish a link between obstetric complications and schizophrenia. 5 Likewise, the suggested reduced risk of cancer in patients diagnosed with schizophrenia is still debated. 6, 7 We think that an evolutionary epidemiological analysis can help better assess these issues. 8 Evolutionary epidemiology looks for explanation of the persistence of genetically based traits that are maladaptative in terms of survival and fertility. 9, 10 Schizophrenia is a serious, chronic disorder, which negatively impacts the lives of affected patients, their families as well as society at large. The clinical course is typified by highly recurrent acute episodes with chronic impairment of social, vocational, and personal well-being. [11] [12] [13] The costs for patients, their families and society are huge. 14, 15 More complete knowledge of the etiology of this disorder might lead to earlier detection of symptoms, more effective treatments and, ideally, directly preventative interventions. Such a complete understanding will entail not only analyses of complex ontogeny but also more intensive study of the phylogenetics of schizophrenia.
Recent systematic meta-analyses of studies of the epidemiology of schizophrenia reported a median incidence of 15.2/ 100,000 persons (80% CI=7.7-43.0), and a median prevalence of 4.0/1,000 persons (80% CI=1. 8-11.6) , with a lifetime morbidity risk of 7.2/1,000 persons. 16 The risk is higher among males than females, with a risk ratio=1.4/1.
Family, twin, and adoption studies of schizophrenia confirm a significant but not complete hereditary basis. Odds ratio of familial aggregation of schizophrenia is quite high, on average 6 to 15. 17 In adoption, the risk is consistently higher in biological versus adoptive clusters. 18 In twins, the risk is higher among monozygotic than dizygotic pairs. Genetic heritability attributable to non-shared environment is estimated at 81%, with a scant 11% attributable to environmental effects shared by the members of a twin pair. 19, 20 However, the genetics of schizophrenia remain far from clear. According to a synthesis prepared by Gottesman and Erlenmeyer-Kimling, 21 prevalence is consistently higher among first-degree relatives of patients-from 6% of parents to 13% of offspring. However, up to 63% of patients have no first-or second-degree relative with the disorder. Moreover, the prevalence of schizophrenia is 48-53% among monozygotic twins (as against 15-17% in dizygotic twins).
Additional factors have been reported to be involved in the etiology and developmental onset of schizophrenia, notably place or time of birth, infections during pre-and peri-natal development, obstetric complications during pregnancy or labor (Table 1). Nevertheless, a family history of psychosis is still by far the strongest predictor of schizophrenia in a given subject. [22] [23] [24] What is schizophrenia, really?
Despite a century of investigation, diagnosis of schizophrenia relies solely on clinical evaluation of symptoms, with no reliable laboratory test to distinguish affected patients from healthy people. Indeed, there is good evidence for global alterations in brain structure and subtle abnormalities in physiological and neurochemical functioning, but few are specific to schizophrenia or have sufficient effect size to allow diagnosis differentiation. 25 Over time, this difficulty has led to increasingly nihilistic positions, such as claims that schizophrenia is not a distinct or coherent nosological entity but an epistemological delusion without a real basis in nature. 26 Others propose to subsume schizophrenia into a more general class of psychosis, or meld it within an even more general affective-psychotic continuum. [27] [28] [29] Clearly, lack of external validators seriously hampers the investigation of the epidemiological, clinical and neurobiological correlates of the disorder.
MORBIDITY AND MORTALITY IN SCHIZOPHRENIA
Current criteria for diagnosis of schizophrenia refer to a prototypical condition subdivided into variants based on associate symptoms, clinical course, and response to treatment, among other considerations. 30 Patients diagnosed with schizophrenia by current criteria suffer a higher risk of premature mortality-they die much earlier on a modal basis compared to the life expec- tancy of the general population. These risks are higher for both natural 13, 31 and violent causes, 32 particularly suicide. 33 Higher risk of premature mortality in patients with schizophrenia depends on increased incidence of somatic diseases in these patients, largely as a consequence of psychopathology. 12 A higher risk has been reported for infections such as tuberculosis and virus disease [34] [35] [36] respiratory tract diseases, 37 nutritional and metabolic disorders [38] [39] [40] and cardiovascular disease. 41, 42 Even adjusted mortality due to poor dental hygiene among persons poses an important burden on patients suffering schizophrenia. 43, 44 The main causes of greater rates and severity of somatic diseases in patients diagnosed with schizophrenia include unhealthy lifestyle and poor adherence to treatment, notably medication. 45, 46 Conversely, the often-significant adverse consequences of prescribed antipsychotic therapy directly increase a number of serious illnesses, notably the 'metabolic syndrome' . [47] [48] [49] Yet some recent studies and meta-analyses indicate patients diagnosed with schizophrenia have a reduced incidence of cancer and neoplasms. 7, [50] [51] [52] [53] Such a reduced risk of cancer in patients strongly suggests that somatic factor(s) co-occuring with schizophrenia are protective against cancer.
Inclusive fitness in schizophrenia
From an evolutionary point of view, survival is not merely due to adaptation to the environment. In Darwinian terms, individual fitness refers to differential replication of one' s genes in the next generation, that is, mating success. The ability to rear offspring is essential in achieving individual fitness. Ultimately, individual fitness entails: 1) securing nutrients and other resources for survival, 2) avoidance of death before reproduction, and 3) finding mates to beget offspring, and then 4) rearing of them until sexual maturity and reproduction of the lineage.
The increase in the number of one' s genes in subsequent generations also includes non-offspring kin, as a function of the percentage of genes by direct descent from a common ancestor. This is inclusive fitness, which refers to the total replication of genes in the subsequent generation via both direct (offspring) and indirect (kin) carriers. 54, 55 Some older studies reported a trend towards higher fertility rates in patients' relatives. 56, 57 On the other hand, most studies have reported lower fertility rates in schizophrenia, [58] [59] [60] and no compensatory fertility in relatives. 61, 62 Clinical experience is that patients suffering from severe mental disorders tend to have a lower chance of mating-social incapacities form barriers to the tasks of finding a partner, having children, and then rearing them to maturity. The practice of detaining patients with severe mental disorders in locked mental health hospitals surely contributed to reduce their reproductive opportunities. Studies on this non-secondary aspect of the life of patients with schizophrenia are pending in countries where provision of care for patients with mental disorders is covered by networks of community mental health outpatient centers that have expanded as hospitals closed. 63 The paradox of a disorder with a general population prevalence of nearly 1%, with a robust genetic basis, but lower fecundity and no fertility compensatory advantage in relatives, taken together suggests that the genetic aberration linked to this illness must also carry with it a heretofore unrecognized evolutionary advantage. 64 As yet, attempts to identifying any unrecognized evolutionary advantages have been challenging and largely unsatisfactory. However, factors linked to reduced risk of cancer could have been a powerful selective advantage in phylogeny.
CANCER AND SCHIZOPHRENIA
In a recent meta-analysis, Catts et al. 7 found that the overall cancer incidence rates in patients suffering from schizophrenia were not significantly higher than those in the general population. This was despite the high load of risk factors for cancer among patients with schizophrenia, including smoking, alcohol abuse, obesity, poor diet, and non-adherence to medical advice. Indeed Catts et al. 7 found a reduced risk of colorectal cancer, malignant melanoma, and prostate cancer among patients with schizophrenia compared to the general population, and a reduced impact of smoking on lung and bladder cancer risks.
Remarkably, that patients suffering from schizophrenia have a lower risk of cancer is a long-recognized feature of the disorder, 65 with reports as early as 1909, 66 although such reports do not constitute a consensus. 67 While important negative results have been reported, other surveys describe an enhanced, rather than decreased, cancer risk among patients diagnosed with schizophrenia. 6, 68 Nevertheless, patients with schizophrenia tend to be early, heavy, and long-term smokers of cigarettes; 69, 70 so, much higher rates of cancer among persons with schizophrenia ought to be evident given such exposure to a recognized risk factor for many types of cancer. 71 Beyond smoking as a major risk factor, such patients are less able to pay proper attention to other broad health factors, notably a balanced diet or regular exercise. Moreover, high rates of substance use disorder that cooccur with schizophrenia are an additional source of cancer risk. [72] [73] [74] Smoking, alcohol use, and life-style differences are not the only explanations for the distinct differences in cancer prevalence noted within the general population. Exposure to carcinogenic chemical compounds in the workplace could represent a greater risk factor for some types of cancer than smoking or eating less fruit and vegetables than suggested by current health guidelines. 75, 76 If so, persons with schizophrenia, by inference from their much higher rates of unemployment, may be expected to have fewer cancers. Similarly, some have posited that antipsychotic pharmacotherapy itself may have both direct 77, 78 and indirect anticancer effects (such as hormonal modulation by dopamine). These might contribute to the lower rate of cancer occurrence in schizophrenia. 79, 80 Indeed, perhaps the best evidence of lower risk in patients with schizophrenia is with prostate cancer, 81 a condition considerably influenced by hormones affected by antipsychotic drugs. In the aging male, prostate cancer occurs more commonly amid rising levels of estrogen and decreasing levels of androgen. 82 The prolactin-inducing property of most antipsychotic drugs has a subsequent negative feedback on estrogen levels. 83 This might reduce risk of prostate cancer in patients treated with antipsychotic drugs, despite representing per se a risk factor for other types of cancer. 84 On the other hand, rates of breast cancer are increased in women with schizophrenia but at a rate lower than expected from known risk factors; among others, null-parity, obesity, poor diet, and hyperprolactinemia related to antipsychotic medication exposure. 7 The pathways to reduced risk of cancer in schizophrenia are manifold. Cancers are conditions often occurring in later life. Causes of death exclude each other: someone who dies by suicide cannot die by cancer. Since patients with schizophrenia often die at a younger age than the general population, they may not have the time to develop certain cancers. Psychiatric patients might be less likely to be screened for cancer, or may be more frequently lost in follow-up, and also were known to be less likely to report physical symptoms, 85 though patients rarely ignore advanced symptoms of cancer, such as pain. Finally, the epigenetics and epiphenemics of schizophrenia itself may confer some kind of genetic protection against cancer.
A role for genetics
A recent report from Israel offers clear evidence that the lower risk of cancer extends to patients' close kin. Both the parents and siblings of subjects with schizophrenia had a statistically significant lower risk of cancer, with the clearest evidence noted in reduced cancers of the breast and prostate. 86 These Israeli findings parallel a prior publication of a national cohort of individuals born in Finland between 1940 and 1969 who were treated for schizophrenia between 1969 and 1991. 6 However, another population study carried out on the Danish Central Registries on Psychiatry and Cancer reported negative findings. 87 With respect to the Israeli study, the lower risk of morbidity for cancer in both index cases and blood relatives strongly points to a genetic influence. The patient group, less likely to have a job, is perhaps less exposed to chemical carcinogenic compounds and/or may gain some benefit from as yet unknown protective effects of antipsychotic medications. However, such mechanisms cannot account for the reduced risk in their bloodkin. It is unclear if patients' relatives are more health-conscious than the affected kin, i.e., smoke less than the general population, as this has not been studied. It is pertinent that the Israeli study did tally schizophrenia diagnoses in the sample of relatives and the exclusion of those with schizophrenia did not change the findings. Healthy parents and siblings of patients with schizophrenia still showed a lower risk of cancer than the comparison group.
There are few doubts that genetics plays a relevant role in increasing, or decreasing, the risk of cancer within components of the general population. [88] [89] [90] Some studies suggest very simple genetic mechanisms may have a major role in many familial cancers;
91,92 the Lynch Syndrome was perhaps the first confirmation of a mendelian cancer, in the colon. 93, 94 So too, yet unknown genetic factors linked to the reduced risk of cancer in schizophrenia could have a role in the etiology of the disorder.
GENETICS, OBSTETRIC COMPLICATIONS, AND SCHIZOPHRENIA: THE MISSING LINK?
The etiology of schizophrenia remains unknown, and its genetics is quite puzzling: heritability is 70-85%, yet 60% of the people diagnosed with schizophrenia have neither a first, nor a second-degree affected relative. 21, 95 Moreover, concordance in twins oscillates between 15 and 58% 21, 96 indicates some role for post-translational epigenetic factors. 97, 98 Large-scale surveys have identified a wide range of susceptibility genes, 99 but the specificity of these genes to schizophrenia is questionable, and attempts to replicate findings were often unsuccessful. 100, 101 While it is unlikely a single gene is responsible for schizophrenia, the issue is clouded by vast problems in proper clinical description of a true epigenetic phenotype that is separable from similar acquired syndromes. 8 Drawing from past formulations, 10, 64 an oligogenic, mutationselection balance model has been proposed to explain inconsistencies in the identification of susceptibility genes in schizophrenia. In this model, a relatively small number of alternative alleles are maintained because their net fitness effects balance each other, so the alleles are not lost by chance or genetic drift. 102, 103 Such a mechanism could imply some gene-environment interaction, 104, 105 whereby a genetic profile is associated with an enhanced risk of suffering from adverse events on a neurodevelopment basis (Figure 1) .
Studies of both animals and humans point to the possibility environmental events might impact genetic predisposition to abnormal reactions after CNS lesion, causing deviations in the natural course of brain maturation that may result in neuropsy-chiatric disorders. [106] [107] [108] [109] [110] Pre-/Peri-natal complications are thought to disrupt normal fetal brain development, thus disorganizing both the cerebral micro-architecture and neural network interlacement. Pre-/Peri-natal complications most often associated with schizophrenia in general lead to hypoxic-ischemic damage. 5 However, major fetal brain anoxia -likely to result from severe obstetric complications -generally leads to death or to marked motor impairment.
111,112 Therefore, we infer that some brain-protecting gene would be necessary to balance the brain-damaging impact of severe obstetric complications: whenever obstetric complications occur, schizophrenia would develop only in the presence of the protective gene. 105 However, even less severe obstetric complications may cause deviation in neurodevelopment when alleles enhancing the impact of these obstetric events are present, and again the co-occurrence of brain-protecting gene would prevent the worst consequences of the resulting brain damage (death or severe cognitive or motor impairment).
A link between obstetric complications and schizophrenia is now well established and the effect is small, but consistent. 113, 114 Past studies found that certain epigenetic conditions increasing the risk of obstetric complications are also associated with a higher risk of schizophrenia, e.g., Rh-incompatibility. 115, 116 Obstetric complications also tend to recur within families and cluster in families with a larger number of subjects diagnosed with schizophrenia. 117 In addition, mothers of children who later suffer from schizophrenia themselves have enhanced risk of unfavorable outcome in pregnancies other than the index case. 118 Conversely, siblings of patients with schizophrenia incur greater frequency and severity of pregnancy and birth complication than do healthy controls. 119 Such evidence suggests the genetics of schizophrenia might be explained, in part, by the related genetics of conditions that increase risk of obstetric complications. 105, 120 Even where there is seemingly equal exposure to risk, as in the case of twins, one twin may actually be more at risk. Such variations may help explain the incomplete concordance of schizophrenia in identical twins. Indeed, McNeil and coworkers 121 noted that labor complications in monozygotic twins were significantly more frequent in twins discordant for schizophrenia.
Thus a wide range of mechanisms -inflammatory, immune, and/or vascular basis -may be processes etiogenic of schizophrenia. These range from initial pre/peri-natal brain insults, to neuronal reorganization and synaptic plasticity in adolescence (the "second hit" in Figure 1) , and finally to the onset of psychosis. 105, 122, 123 Though heavily genetic, schizophrenia is also subject to considerable environmental influence. 104, 105 But, what kind of genes could be involved, both related to cancer and expressing some protective effect on the neurodevelopment?
POTENTIAL PATHWAYS IN THE REDUCED RISK OF CANCER IN SCHIZOPHRENIA
In their attempt to explain the lower cancer risk in parents and siblings of patients with schizophrenia, Levav and co-workers 86 hypothesized a role for the tumor suppressor p53 gene. 124, 125 This gene is but the first of the many with possible implications for reduced risk of cancer in schizophrenia. There are other candidate genes, including:
-Adenomatous polyposis coli gene, tumor suppressor that is significantly associated with schizophrenia; 126 -The fragile site, aphidicolin type, common, fra(6)(q21) (FRA6F), a site of unusual chromosomal fragility, is likely to carry a tumor suppressor gene in a region that also maps to a gene Figure 1 . The "two/three-hits" neurodevelopmental hypothesis of schizophrenia.
Genetically-based anomaly
Step one
Step two -Phosphatidylinositide 3-kinase-protein kinase B pathway genes are involved in cellular growth and proliferation. These activities are reduced in schizophrenia, which may logically protect against cancer; 2 -Neuregulin-I/ErbB signalling system genes modulate cell proliferation, migration, differentiation, and survival or apoptosis. 128, 129 Neuregulin-I attenuated signaling is seen in animal models of schizophrenia; 128, 130 -Bombesin-activated pathway genes have bombesin-like peptides that act as growth factors in the pathogenesis of several human cancers. 131 Patients with schizophrenia have lower levels of bombesin than do non-schizophrenic subjects; 132 -Neurotensin genes implied in the activity of antipsychotic drugs. 133 Neurotensin also down-regulates neuropeptides autocrine growth factors active in cancer lines.
Additional mechanisms may be involved. MicroRNAs -noncoding RNA molecules thought to regulate expression of many mRNAs -are implicated in the etiology of several types of cancer and expressed at a lower level in patients with schizophrenia. 134 Likewise, short tandem repeat (STR) replacements in untranslated sequence (UTR), putatively involved in both schizophrenia and cancer. 135 
THE ROLE OF DEVIANCE IN NEURODEVELOPMENT
Apart from cancer, people with schizophrenia not only have reduced prevalence of diabetes mellitus type 1 136 and rheumatoid arthritis 137, 138 but both conditions are influenced by genes that control immune and inflammatory systems -genes that may also influence obstetric complications on neurodevelopment.
Immune-mediated conditions share with schizophrenia a propensity to atypical handedness (increased left-handedness and/or mixed-handedness), which is associated with many neurodevelopmental disorders. [139] [140] [141] Additionally, a wide range of genes can influence, positively or negatively, the chances of cancer development. These include genes involved in control of immune-surveillance, 142, 143 inflammation, [144] [145] [146] vascular proliferation, [147] [148] [149] and apoptosis. 128, 150 Most of these genes are also involved in neurodevelopment, guiding neuron proliferation and rearrangement. Nicodemus et al. 151 reported four genes -AKT1, brain-derived neurotrophic factor (BDNF), glutamate receptor 3 (GRM3), and dystrobrevin-binding protein 1 (DTNBP1)-are potentially involved in hypoxia/ischemia and/or the integrity of cerebrovasculature structures. These four genes are expressed in a nonrandom fashion among patients with schizophrenia who experienced obstetric complications during pregnancy. Moreover, these genes have a demonstrable neuroprotective role. 152 The Nicodemus study is the first to assess a plausible hypothesis of gene-by-environment interaction in schizophrenia risk.
All these genes might exert their effects through the wellknown mechanisms of pleiotropy and epistasis, 153 as the same genes that protect the brain from excessive perinatal damage may also both foster later development of schizophrenia yet protect against cancer.
EVIDENCE FOR ADAPTIVE EVOLUTION OF GENES INVOLVED IN SCHIZOPHRENIA
Crespi and co-workers 154 found evidence of positive selection of genes involved in the etiology of schizophrenia. HapMap-based analyses showed evidence for positive selection on 14 genes associated with schizophrenia. Stronger statistical evidence was noted for DTNBP1 and the GRM3. Positive selection was found in additional 4 genes in the human -compared to chimpanzee-or primate-origin lineages. These genes are neuregulin 1 (NRG1), proteolipid protein 1 (PLP1), tenascin XB (TNXB), tumour protein p53 (TP53). Also, the 'disrupted in schizophrenia' gene (DISC1) showed positive selection in the human lineage, with evidence of acceleration in the coding region repeatedly associated with schizophrenia. 154 More recently, a meta-analysis of the SchizophreniaGene database found 8 potential candidate genes whose polymorphisms are statistically associated with schizophrenia. 155 Some correlated to enhanced risk of schizophrenia in carriers: TP53, dopamine receptor D4 (DRD4), 5,10-methylenetetrahydrofolate reductase (MTHFR), protein phosphatase 3 [formerly 2B] catalytic (PPP3CC), and gamma-aminobutyric acid A receptor, beta (GABRB2). Conversely, others were associated with reduced risk of schizophrenia: D-amino acid oxidase (DAO), solute carrier family 6 member 4 (SLC6A4, also known as 5-hydroxytryptamine transporter or 5-HTT), and interleukin1 and beta proprotein (IL1B). This is fully compatible with the hypothesis that both protective and aggravating genes play a role in the etiology of schizophrenia.
IMPLICATIONS FOR RESEARCH
Neither reduced risk of cancer nor the recently reported reduced mortality by cerebrovascular incidents 13 cause genes etiogenic of schizophrenia to persist in the general population. Cancer or stroke typically occur well after sexual maturation and the reproductive cycle so neither should impact inclusive fitness of the individual. Thus, evidence that schizophrenia confers reduced risk of certain somatic diseases, if confirmed, is highly significant information for evolutionary epidemiological analyses. This association is presumably mediated by important genetic elements in systems that involve immune-surveillance, inflammation, vascular proliferation or apoptosis. Moreover, the association points to pleiotropic or epistatic etiogenes that not only induce schizophrenia but also confer protective somatic effects evident after the onset of psychosis. Though rather complex as pleiotropy and epistasis ever are, such associations evidently conferred distinct adaptive advantages in the environment of evolutionary adaptation. 8 Indeed, these genes might have contributed to speciation, by protecting the fetus brain from increasing risk of damage in early environment. Among major factors that confer to the human fetus a higher risk of injury and infection are: large ratio of fetal head to maternal pelvic outlet size, presentation in occipital position (rather than face up, as in the apes), and prolonged labor and delivery in humans compared to other anthropoids. 156 As delineated in this and prior papers, 105 ,120 schizophrenia could only develop when environmental events impacting the fetus in pregnancy and the perinatum (that occur within still to be identified temporal windows), thereby affect specific regions of the developing brain in presence of protective genes which prevent death or severe motor or cognitive impairment. Schizophrenia does not persist because it protects from cancer or stroke, but because genes that offer such somatic protection are essential in successful navigation of earlier developmental phases where schizophrenia arises.
However, it is unlikely schizophrenia has a single etiological cause. It is possible that schizophrenia-like syndromes following obstetric complications merely converge in disrupting mechanisms implicated in other heritable forms of psychoses diagnosable as "schizophrenia" endophenotypes according currently shared criteria. Hemispheric lateralization is one notable example wherein developmental disruptions often give rise to psychosis. 157 Indeed, obstetric complications often result in abnormal hemispheric specialization [158] [159] [160] of the kind more often reported in schizophrenia. 161, 162 Evolutionary sciences in general and evolutionary psychiatry in particular are often criticized for lack of testable hypotheses. 163 Yet practical, ethical study protocols are elusive. 8 Here we have integrated a body of evidence with direct clinical consequences as well as importance to evolutionary interpretation. Moreover and of particular interest to skeptics of evolutionary epidemiological analyses, it is possible to test the pleomorphic and epistatic roles here proposed for genes linked to protection against cancer and schizophrenia.
Patients with schizophrenia should be significantly more likely to screen positive for hereditary disorders linked to increased risk of obstetric complications. 105 Conversely, persons born with hereditary disorders that may increase risk of obstetric complications may have higher prevalence of schizophrenia in their families. Moreover, persons who both suffer from schizophrenia and also experienced obstetric complications should have lower rates of some cancers.
Genetic polymorphisms that increase chances of neoplasia should be less common among persons with schizophrenia and their families. Conversely, genetic polymorphisms that decrease chances of neoplasia should be more common among persons with schizophrenia and their families. Patients who suffer from schizophrenia should be found to down-regulate genes and systems that increase cell proliferation, migration, differentiation, and survival or apoptosis, hence increasing the chance of cancer. Finally, the relationships between cancer and schizophrenia may span a multitude of regulatory pathways and genetic polymorphisms. Thus a rational approach should focus on factors that are more likely to moderate the consequences of prenatal and perinatal complications. Here we posit that such specific factors involved in cancer development and proliferation are also likely to be important in the development of schizophrenia.
Some preliminary findings are consisting with these expectations. The most common haplotype block of MET proto-oncogene (MET) is primarily linked to tumor metastasis. This haplotype was found in patients with schizophrenia statistically less often than in healthy controls. 164 The Matrix metalloproteinase-9 (MMP9), also known as gelatinase B, 92 kDa gelatinase, or 92 Da type IV collagenase, is involved in cancer and cardiovascular disorders. In particular, the functional -1562 C/T polymorphism of the MMP9 gene confer a higher risk of cardiac mortality and more severe progression of some type of cancer: a diminished frequency of the T allele of the MMP9 gene was reported in patients diagnosed with schizophrenia. 165 It is notable genes specifically disrupted in schizophrenia operate in interacting pathways but most are related to the development of the neural and immune systems. 166, 167 Further investigation of the links between schizophrenia and cancer will reveal much about the etiology of psychosis and will also cast light on a variety of somatic illnesses associated with schizophrenia and cancer through pleomorphic and epistatic mechanisms. The discovery of pathways that lead from pre-and/ or peri-natal insult caused by obstetric complications onto the manifestation of schizophrenia should advance therapeutics as well. Such discoveries may facilitate preventive measures in early development and may also guide screening and treatment for those types of cancer with reduced incidence in schizophrenia. Presently, early evidence is most robust for a role of genes protective in cancer that increase risk of schizophrenia -and vice versa. More expansively, this evolutionary epidemiological approach will likely trace many new and unexpected medicalpsychiatric pleomorphies and epistases.
